The MAO Inhibitor Tranylcypromine Alters LPS- and Aβ-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD
Authors:
- HyunHee ParkHPHyunHee Park
- Kyung-Min HanKHKyung-Min Han
- Hyongjun JeonHJHyongjun Jeon
- Ji-Soo LeeJLJi-Soo Lee
- Hyunju LeeHLHyunju Lee
- Seong Gak JeonSJSeong Gak Jeon
- Jin-Hee ParkJPJin-Hee Park
- Yu Gyung KimYKYu Gyung Kim
- Yuxi LinYLYuxi Lin
- Young-Ho LeeYLYoung-Ho Lee
- Yun Ha JeongYJYun Ha Jeong
- Hyang-Sook HoeHHHyang-Sook Hoe
Open Access
Abstract
Monoamine oxidase (MAO) has been implicated in neuroinflammation, and therapies targeting MAO are of interest for neurodegenerative diseases. The small-molecule drug tranylcypromine, an inhibitor of MAO, is currently used as an antidepressant and in the treatment of cancer. However, whether tranylcypromine can regulate LPS- and/or Aβ-induced neuroinflammation in the brain has not been well-studied. In the present study, we found that tranylcypromine selectively altered LPS-induced proinflammatory cytokine levels in BV2 microglial cells but not primary astrocytes. In addition, tranylcypromine modulated LPS-mediated TLR4/ERK/STAT3 signaling to alter neuroinflammatory responses in BV2 microglial cells. Importantly, tranylcypromine significantly reduced microglial activation as well as proinflammatory cytokine levels in LPS-injected wild-type mice. Moreover, injection of tranylcypromine in 5xFAD mice (a mouse model of AD) significantly decreased microglial activation but had smaller effects on astrocyte activation. Taken together, our results suggest that tranylcypromine can suppress LPS- and Aβ-induced neuroinflammatory responses in vitro and in vivo.Keywords
Funding Information
- National Research Foundation of Korea (2019R1A2B5B01070108, NRF-PG20190124)
This publication has 52 references indexed in Scilit:
- A Systematic Analysis of the Peripheral and CNS Effects of Systemic LPS, IL-1Β, TNF-α and IL-6 Challenges in C57BL/6 MicePLOS ONE, 2013
- Multitarget-Directed Benzylideneindanone Derivatives: Anti-β-Amyloid (Aβ) Aggregation, Antioxidant, Metal Chelation, and Monoamine Oxidase B (MAO-B) Inhibition Properties against Alzheimer’s DiseaseJournal of Medicinal Chemistry, 2012
- IL-6 Trans-Signaling Modulates TLR4-Dependent Inflammatory Responses via STAT3The Journal of Immunology, 2011
- Alzheimer's DiseaseNew England Journal of Medicine, 2010
- Age influences the effects of nicotine and monoamine oxidase inhibition on mood-related behaviors in ratsPsychopharmacology, 2010
- Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contentsJournal of Neural Transmission, 2008
- Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and BBioorganic & Medicinal Chemistry Letters, 2008
- A new role for monoamine oxidases in the modulation of macrophage-inducible nitric oxide synthase gene expressionJournal of Leukocyte Biology, 2004
- Monoamine Oxidase B Induces ERK-Dependent Cell Mitogenesis by Hydrogen Peroxide GenerationBiochemical and Biophysical Research Communications, 2000
- Selective MAO-A and B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's deseaseLife Sciences, 1994